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Abstract
Low- and middle-income countries need to consider
economic issues such as cost-effectiveness,
affordability and sustainability before introducing a
program for human papillomavirus (HPV) vaccination.
However, many such countries lack the technical
capacity and data to conduct their own analyses.
Analysts informing policy decisions should address
the following questions: 1) Is an economic analysis
needed? 2) Should analyses address costs,
epidemiological outcomes, or both? 3) If costs are
considered, what sort of analysis is needed? 4) If
outcomes are considered, what sort of model should
be used? 5) How complex should the analysis be? 6)
How should uncertainty be captured? 7) How should
model results be communicated? Selecting the
appropriate analysis is essential to ensure that all the
important features of the decision problem are
correctly represented, but that the analyses are not
more complex than necessary. This report describes
the consensus of an expert group convened by the
World Health Organization, prioritizing key issues to
be addressed when considering economic analyses to
support HPV vaccine introduction in these countries.
Keywords: Human papillomavirus, vaccination, low-
and middle-income countries, economic evaluation.
Background
The World Health Organization (WHO) recommends
that cost-effectiveness be considered before human papil-
lomavirus (HPV) vaccination is introduced in national
programs [1]. However, many low- and middle-income
countries (LMICs) lack the technical capacity and accurate
empirical data to develop and parameterize de novo mod-
els of complex interventions such as HPV vaccination
[2-5]. Given these constraints, LMIC decision-makers may
want to apply or adapt a previous economic evaluation
conducted in a different country. The practice of adapting
existing models is common: one systematic review of eco-
nomic evaluations of HPV vaccination found that 35 of 58
relevant articles were adaptations of previous models [6].
However, most existing analyses (44/58) were set exclu-
sively in high-income countries (HICs). Hence, analysts in
LMICs who want to understand whether they should
adapt a previous model, develop a new one, or not con-
duct an economic evaluation at all have fewer examples
and guidance on which to rely.
Furthermore, analysts often face a dilemma in choosing
which models to develop or adapt. On the one hand, sim-
pler models are easier to parameterize, adapt, and inter-
pret; however, such models are designed to answer a
limited range of questions, and can be misleading if used
to address more complex issues [7,8]. On the other hand,
models that are equipped to address more complex issues
may require expertise or data that may not be available in
that country.
In addition to cost-effectiveness results, decision-makers
may need to know the financing requirements and afford-
ability of vaccine introduction to support financial plan-
ning and forecasting. Such considerations are informed by
models that comprehensively capture the programmatic
costs and logistic considerations involved in national
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any medium, provided the original work is properly cited.scale-up of vaccine introduction [9], but are less focused
on reproducing the natural history and epidemiology of
HPV-related diseases.
A further challenge is translating economic results into
conclusions that are useful to decision-makers. In parti-
cular, decision-makers need to understand the type of
policy questions that economic models can address, and
the appropriate caveats around model conclusions (such
as data shortcomings and model uncertainty).
To address these questions, the WHO convened a
panel of modelers and economists to develop guidance
for analysts based in LMICs who advise policy-makers on
HPV vaccination (but based on principles applicable to
all countries). Panel members held several meetings to
outline issues, then agreed on a summary. Each member
then drafted sections of the guidelines, then received
comments from all other participants. Comments were
collated, harmonized and further reviewed by all partici-
pants until complete consensus was reached. Full details
of guideline development are available in the Appendix.
Question 1: Is an economic analysis needed?
Three ways to use economic analyses to inform decisions
around HPV vaccination are: 1) conducting no structured
analysis, 2) borrowing insights from analyses in other set-
tings, and 3) conducting a de novo country-specific analy-
sis using an economic model.
The option of not conducting any analysis is particu-
larly attractive in LMICs with limited analytical capacity.
However, such countries may also have the greatest need
for evidence, because poor allocation of funding at the
margin has greater health consequences when funds are
limited.
Policy-makers may also consider using existing analyses
and insights from other settings. When analytical results
are stable across settings, conducting new setting-specific
studies may add little value. For example, model conclu-
sions about vaccinating girls before onset of sexual activity
have been similar across HICs [7,8]. There have been
fewer results from LMICs, but existing analyses suggest
that HPV vaccines need to be priced much more competi-
tively in LMICs than in HICs for vaccination to be cost-
effective [6,10].
Vaccine price, HPV prevalence, and uptake of cancer
screening and treatment are key drivers of the cost-
effectiveness of HPV vaccination in LMICs [6,10].
Hence, studies investigating similar policy questions in
settings where such parameters are similar can be
adapted to a new setting. Many parameters that vary
across settings (such as unit costs) are usually easy to
adjust for in economic models. Hence, before deciding
whether to conduct a de novo analysis, decision-makers
should consider existing analyses, investigate the main
drivers of results in similar countries, and appraise the
extent to which these analyses are suited for their own
country. Ideally, such a process should be transparent
and unbiased, using best-practice methodology for evi-
dence review and synthesis [11].
Question 2: Should analyses address costs,
epidemiological outcomes or both?
Once a decision is made to conduct an economic eva-
luation, the type of analysis needs to be chosen. First, a
clear, answerable policy question is defined [12]. This
will determine 1) which costs and/or health outcomes
(for example, cervical-cancer incidence or disability-
adjusted life years (DALYs) lost) are considered, 2) what
the intervention and comparator under evaluation are,
3) who the target audience is, and 4) what methodologi-
cal options (such as time horizon and economic per-
spective) are chosen.
Analyses involving costs alone usually use primary
data from demonstration projects and other studies
exploring different HPV vaccine delivery programs [9].
These are useful for several reasons. Firstly, vaccine pur-
chase costs are often borne by external donors who
make decisions based on their own analyses. However,
national decision-makers still need to investigate
whether vaccine delivery is affordable in the short term
and sustainable in the long term. Secondly, if vaccina-
tion is introduced, planners need to allocate resources
for the financial costs of introducing the vaccine.
Thirdly, these data inform cost minimization studies
that address questions such as optimal delivery strategy
(school-based, health facility-based, using national
immunization days, or a combination). They also inform
budget impact analyses, and are essential inputs into full
economic evaluations such as cost-effectiveness analyses.
Alternatively, models may project the effects of vacci-
nation on disease burden [13], using measures such as
cervical-cancer morbidity, mortality, or DALYs. These
studies are essential inputs for cost-effectiveness ana-
lyses, but are also useful in their own right to inform
surveillance and to understand emerging post-vaccina-
tion trends such as changes in the average age of infec-
tion, waning vaccine effectiveness, herd immunity, and
potential type replacement. They can also show if vacci-
nation is equitable in terms of how its effects are dis-
tributed by income strata, geographical location, ethnic
group, and gender.
For setting priorities, full economic analyses consider-
ing both costs and outcomes are needed. Such analyses
address whether HPV vaccination is worth the invest-
ment compared with either current practice such as
existing cervical-cancer screening and treatment [14] or
doing nothing [15]. They can also address more detailed
questions such as the choice of vaccine (bivalent or
quadrivalent), target ages for routine and catch-up
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program [16], and revising screening policies to opti-
mize synergies with vaccination [8].
In HICs, economic models often inform evidence-
based priority-setting discussions through National
Immunization Technical Advisory Groups (NITAGs)
[17]. In LMICs, priority-setting discussions are still rele-
vant, but may not be held because of lack of capacity to
perform local evaluations and/or the absence of advisory
groups to interpret results. In addition, decisions are
often driven by donors such as international funding
agencies or individual donor countries, so spending
priorities are set by the international community.
Therefore, more pragmatic analyses such as budget
impact analyses focusing on cost savings, affordability,
and sustainability may be more relevant in these coun-
tries [18].
Question 3: If costs are considered, what sort of
analysis is needed?
An economic analysis involving costs involves the fol-
lowing steps.
1) Plan a data-collection study, which can be either
retrospective or prospective.
2) Choose between calculating financial or economic
costs (or both).
￿ Financial costs are the value of resources to the
payer (such as the Ministry of Health), and are used
to assess affordability. They include actual resources
purchased such as injection supplies, outreach and
daily allowances, and funds for training and develop-
ing new communication materials.
￿ Economic costs comprise the opportunity costs of all
outlays, including resources already paid for or owned
by the Ministry of Health, and other sources of finan-
cing, such as the salaries of health personnel, vaccines
paid for by partners, and donated equipment or ser-
v i c e ss u c ha sv o l u n t e e rt i m e .T h e yg i v eam o r ec o m -
plete picture of resources that are tied up in the
provision of the new vaccine and their opportunity
costs, and should be used if a cost-effectiveness or
cost-benefit analysis is to be conducted. They are also
used to evaluate sources of required financing for
introduction and scale-up, and to assess the feasibility
of providing the necessary health system requirements
on a sustainable basis. They also give a better assess-
ment of the share of costs financed by different part-
ners including external partners, because they include
the value of donated goods.
3) Choose between calculating costs using an ingredi-
ents approach, or using average costs.
￿ An ingredients approach estimates the quantity and
cost of each individual resource required by a pro-
gram [19]. This is the preferred approach to evaluate
the value of resources used to introduce HPV vacci-
nation because the service-delivery strategies used are
different from those used for infant vaccines.
￿ Average costs based on administrative returns or tar-
iffs are often used in economic evaluations in HICs, on
the basis that delivery costs are small compared to the
cost of vaccine purchase, and hence inaccuracies in
their estimation are less important. However, such
assumptions may not hold in many LMICs.
4) Choose between incremental costs (the additional
costs that occur with the HPV vaccination (or other
intervention)) or all costs, including shared costs. For
example, the transport costs may be shared with other
vaccines, so would not be fully included in an incremen-
tal analysis. Incremental cost analyses are typically used
for cost-effectiveness and cost-benefit analyses. How-
ever, for partial economic analyses, total cost analyses
can inform comparisons between different strategies.
5) If vaccination is being compared with screening and
treatment, estimate the value of resources used for screen-
ing, diagnosis, and treatment of neoplasias. Even in health
systems without organized screening, there is a need to
account for the cost of providing cancer treatment and
palliative care.
6) Distinguish between recurrent or operational costs
(those lasting less than a year) and capital costs (lasting
longer than a year), so that the value of capital goods
can be spread over a longer period [19].
7) Identify start-up costs needed in the first year of
vaccination, such as introduction costs (microplanning,
initial training, and initial social mobilization material
development) and capital goods (additional cold chain
equipment, vehicle requirements, and incinerators).
Question 4: If outcomes are considered, what sort
of model should be used?
Model choice should be driven by the policy questions to
be answered. The simplest models (termed ‘proportionate
outcomes static models’; Table 1), do not capture indirect
benefits of vaccination (herd immunity), but can still pro-
vide conservative estimates of the cost-effectiveness of vac-
cinating girls before they start sexual activity. They also do
not capture changes in sexual activity, screening behavior,
or demographics.
Proportionate outcomes models assume that cervical-
cancer incidence does not change in the absence of vacci-
nation, so should not be used in countries in which cervical
screening has recently or will shortly be introduced. Ignor-
ing the potential reduction in cervical-cancer incidence
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HPV vaccination. Such situations require the use of ‘static
progression models’ (Table 1), which model the natural
history of disease from HPV infection to cervical cancer,
and the effect of screening on disease progression.
Questions such as the incremental cost-effectiveness
of vaccinating boys, the optimal age of routine and
catch-up vaccination, and the optimal combination of
screening and vaccination, should be examined using
‘transmission dynamic models’ (Table 1) which capture
indirect effects of vaccination [8,20]. Such models are
also required if evidence is needed on the magnitude
and timing of the benefits of vaccination.
Static models overestimate the incremental benefit of
vaccinating boys in addition to girls [20]. This is because
they do not capture the herd protection males already
receive from female-only HPV vaccination programs.
Hence, a dynamic model is needed to show that male vac-
cination is cost-effective, although a static model may be
used to confirm that vaccinating boys is not cost-effective
at all, as the results under the dynamic model will be less
favorable than under the static model. Furthermore, it is
unclear whether using a static model will produce conser-
vative estimates for catch-up strategies. This is because the
potential for incremental gains in the catch-up cohorts
may be smaller under a dynamic framework where some
vaccinated individuals would have been indirectly pro-
tected through herd immunity [8].
Simple static cohort models are usually difficult to
adapt into the dynamic models. Hence, some studies
have captured herd immunity using hybrid models,
which use dynamic models to represent transmission,
and static models to represent disease progression and
screening (Table 1) [15,16,21]. Hybrid models can
address the same policy questions as dynamic models,
but can be incorporated as add-on modules to static
models. Thus, end users can begin with the simpler
model, and then use the hybrid module for more com-
plex questions. The disadvantage of this approach is that
the way in which dynamic model predictions inform the
static model can lack transparency.
Countries or donors may need to choose between the
competing HPV vaccines. Few modeling studies have
directly compared bivalent and quadrivalent vaccines,
and none of these studies have been carried out in
LMICs. Studies in HICs suggest that quadrivalent vacci-
nation is more cost-effective than bivalent vaccination if
they are equally priced, because of the additional benefits
of preventing genital warts [22-24]. In many LMICs how-
ever, preventing cancer may be the main or sole priority
for HPV vaccination, so bivalent vaccination may have an
advantage because of its better cross-protection against
non-vaccine oncogenic HPV types [25]. Such questions
should be addressed using multi-type transmission
dynamic models because 1) static models do not capture
the picture of wart prevention in males as a result of vac-
cinating females, and 2) multi-type models are needed to
accurately capture the different cross-protective effects of
the two vaccines.
Question 5: How complex should the analysis be?
Model types range from simple ‘proportionate outcomes’
spreadsheet models to complex dynamic transmission
models (see Table 1). Complex models may generate more
accurate results and address more questions, but require
additional data, time, effort, and expertise. Using them
may require dependence on external consultants or con-
sume rare local expertise. However, they may also engage
local experts with strong analytical skills in the public
health policy-making process.
Table 1 Types of models involving health outcomes, from least to most complex.
Model type Features Data requirements
Demography Epidemiology Clinical
Static
proportionate
outcomes
model
Reduction in cervical cancer due to
vaccination is the product of effective
vaccine coverage and cervical-cancer
incidence caused by vaccine-type HPV
Population
structure, birth
and death rates
Cervical-cancer incidence, mortality
and proportion caused by HPV 16/18,
by age
None
Static
progression
model
Represents the natural history of disease
from HPV infection to cervical cancer,
usually in a single birth cohort
Population
structure, birth
and death rates
Cervical-cancer incidence, mortality
and proportion caused by HPV 16/18,
by age; female HPV prevalence and
clearance by age
Uptake and efficacy of
screening, diagnosis and
treatment of cancer and
pre-cancer
Transmission
dynamic
model
Captures HPV transmission from infected to
susceptible individuals in the entire
population
Population
structure, birth
and death rates,
sexual behavior
Cervical-cancer incidence, mortality
and proportion caused by HPV 16/18,
by age; HPV prevalence and clearance
by age and sex
Uptake and efficacy of
screening, diagnosis and
treatment of cancer and
pre-cancer
Hybrid model Uses a static progression model to capture
disease natural history, and a dynamic
model to capture infection transmission
Population
structure, birth
and death rates,
sexual behavior
Cervical-cancer incidence, mortality
and proportion caused by HPV 16/18,
by age; HPV prevalence and clearance
by age and sex
Uptake and efficacy of
screening, diagnosis and
treatment of cancer and
pre-cancer
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results increase the probability of a decision aligned with
the decision-maker’s preferences. Oversimplified models
may make poor predictions, leading to worse policy
choices than would have occurred in the absence of
model-based evidence. Hence, sometimes only a sophisti-
cated model is appropriate. For example, if a static model
(which ignores herd immunity) suggests that vaccination
is not cost-effective, then vaccination should not be
rejected without first testing the conclusion using a
dynamic model that will capture more benefits. Similarly,
investigating the relative value of bivalent and quadriva-
lent vaccines, or the precise upper age limit for catch-up
vaccination, require sophisticated models calibrated with
good data.
A second consideration is the trade-off between the
incremental informational value and additional time/
effort needed for a more sophisticated modeling
approach. A model should be as parsimonious as possi-
ble; it should capture effects vital to understanding the
policy questions (such as herd protection when examin-
ing the effects of vaccinating boys on the incidence of
disease in girls), but equally should not have unneces-
sary detail [26]. Determining whether particular effects
are important for decision-making may require a more
complex model to investigate whether the results of the
simpler model are biased. Often, analysts can draw on a
repertoire of simple model structures that have been
validated against more complex models and peer-
reviewed. For instance, a range of HPV models were
recently compared using a standardized input dataset
[6]. Analysts can also draw on methodological work
investigating the effect of different simplifications to
model structure [20]. However, methodological investi-
gations in middle- and high-income settings may not
represent behavioral determinants and disease co-factors
in low-income settings.
The third consideration is the data requirement. Even
simple models require demographic, epidemiological, clin-
ical, and economic data (Table 1). Ideally, these should be
local data from large population-based cohorts or ade-
quately powered trials. When unavailable, less reliable data
sources must be used, such as data from cancer registries
and health care utilization reports (which may be incom-
plete and hence biased), or data extrapolated from other
countries. Complex models may have greater data require-
ments, so data shortcomings may compromise their bene-
fits by introducing additional uncertainty. For example,
transmission models may require data on sexual behavior,
although such data may have been previously collected to
investigate HIV control strategies [27].
However, simpler models do not guarantee reduced
uncertainty, and may indeed increase uncertainty, because
certain aspects of the disease or intervention are not expli-
citly incorporated. Hence, policy-makers short on both
data and technical expertise could focus on more basic
questions that can be robustly answered with simpler
models, and should consider whether their policy decision
can also be informed by adapting insights from other
settings in which sophisticated modeling has been per-
formed with richer data. For example, countries that have
yet to introduce HPV vaccination should first assess the
cost-effectiveness of routine vaccination of girls in early
adolescence, which often can be addressed using relatively
simple models (see Question 4 above). Assessing the cost-
effectiveness of male vaccination requires more technically
demanding analyses, so countries may need to draw
insights from existing studies in high-income [8,28] and
middle-income [16] countries, which suggest that initially
focusing on increasing vaccine uptake in girls is likely to
b eam o r ee f f i c i e n tw a yt or e d u c ec e r v i c a l - c a n c e ri n c i -
dence. In some cases, however, conclusions drawn in
other settings may not apply to low-income countries
because of differences in sexual behavior (such as partner-
ship concurrency), demographic structure, HPV type dis-
tribution, availability of screening and treatment, and
co-factors such as HIV infection.
A fourth consideration is the objective, the intended
audience, and the ultimate use of results of the modeling
exercise. For instance, using a simple model developed by
in-country analysts may build internal capacity for policy
modeling and cost-effectiveness analysis. If capacity to
develop even a simple model de novo is lacking, it may be
possible for local analysts to be advised by external
experts or to adapt a model developed overseas. For
example, models of HPV vaccination in Thailand [14]
and South Africa [29] were developed by independent in-
country analysts adapting an earlier model from the USA
[30]. Many modeling groups are open to adapting their
existing models to new settings in collaboration with in-
country analysts [6]. Another alternative is to develop a
regional network of expertise in using a particular model,
s u c ha st h eP r o V a ci n i t i a t i v ei nL a t i nA m e r i c a[ 4 ]a n d
the PREHDICT (Prevention Strategies for HPV-related
Diseases in European Countries) initiative in Europe [31].
Over time, developing in-country capacity may facilitate
more informed policy analyses and greater use of evi-
dence in decision-making. Even a model developed over-
seas may strengthen capacity if it is parameterized and
interpreted by in-country analysts in such a way that they
gain knowledge of its design. As these analysts grow
more experienced, more complex features such as sexual
partnerships, demographic change, and co-factors such
as HIV infection can be added. Previous experience from
HIV modeling suggests that it may be efficient to build
simple models with sufficient flexibility to incorporate
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and capabilities emerge [32].
In addition, models constructed locally (or in partner-
ship with foreign expertise) help to engage policy-makers
and program managers throughout the analytic process,
potentially leading to a deeper understanding of the local
drivers of health impact and cost, highlighting the value of
data, and increasing awareness of data gaps. Similar
engagement might be reached when a complex model is
accompanied by an easy-to-use interface that local stake-
holders can parameterize themselves. However, results
from simple models may be met with less skepticism
because their structure, inputs and assumptions are gener-
ally more transparent to end users. Lastly, policy-makers
and program managers may feel more ownership of ana-
lyses conducted locally, so the influence of the results may
weigh more heavily in the decision-making process.
Question 6: How should uncertainty be captured?
Models must convey methodological, structural, and para-
meter uncertainty [33]. These respectively arise from dif-
ferent choices made about the analytic methods used (for
example, payer or societal perspective, discounting rates),
underlying model assumptions, and model parameters.
Parameter uncertainty arises when the available input
data give only limited information about the ‘true’ value of
the model parameters. This is particularly important in
settings where available data are limited. Some health
technology authorities such as the National Institute for
Health and Clinical Excellence (NICE) in the UK recom-
mend the use of probabilistic sensitivity analysis to study
parameter uncertainty. This involves specifying a probabil-
ity distribution to represent the uncertainty of each model
parameter, and then propagating this uncertainty to the
outcomes of the analysis (such as the cost-effectiveness
ratio). However, even in developed countries, only a few
HPV modelers have taken this approach [8]. This may be
because HPV models usually contain many parameters
whose uncertainty distributions are hard to quantify, and
whose values are dependent on each other in ways that
require computationally demanding methods to capture.
Instead, many cost-effectiveness analyses rely on univariate
sensitivity analyses instead, where each parameter is varied
within a fixed range and the others kept at their base-case
values. Such an approach may still give insight, but does
not convey the total amount of uncertainty caused by all
parameters.
Structural uncertainty in cervical-cancer models can arise
from model representations of the disease’s natural history
(such as natural immunity mechanisms, progression from
neoplasia to cancer, interaction between HPV types, and
reactivation of latent infections), effectiveness of interven-
tions (such as the long-term efficacy of vaccination, the
effect of vaccine boosting, and the sensitivity of screening
tests for detecting glandular lesions) and population beha-
vior (such as screening attendance, vaccine uptake, and
sexual behavior). In static models, the effect of herd immu-
nity is uncertain because it is not included in the model. If
there are no data to inform such assumptions, structural
uncertainty is explored by constructing different scenarios
representing alternative assumptions. Ideally, the scenarios
should be informed by eliciting expert opinions, and in
some cases, this may allow explicit quantification of the
uncertainty around particular assumptions.
Methodological uncertainty is ideally addressed by hav-
ing a ‘reference case’ specifying the methodological
choices that should be made for all health economic eva-
luations in a country. If this is unavailable, international
guidelines (such as WHO recommendations [12]) can be
used to ensure comparability with evaluations in other
countries, but analysts should also show the conse-
quences of making different methodological choices.
Some methodological choices (such as discount rates) are
based on national considerations such as income growth
rates, so international reference cases may not always be
appropriate.
Question 7: How should model results be
communicated?
Whereas simpler models are likely to have more uncer-
tainty, complex models may be more difficult to explain.
The most important outcome of a decision analysis is
identifying the choice most likely to bring the greatest
benefit (the expected utility-maximizing choice) under
base-case assumptions [34]. However, assumptions and
uncertainties around the outcome must be communicated
so that options to improve data or analysis quality can be
considered, and the credibility of such analyses is not
threatened if the most probable outcomes do not materia-
lize. Unfortunately, when results are presented to deci-
sion-makers, the assumptions, caveats, and sensitivity
analyses are often greatly simplified. To avoid this, com-
munication should be initiated early as an ongoing process
in which key model assumptions are discussed, and their
face validity evaluated to inform later model iterations.
Not all outcomes used in economic evaluations (such as
cost per DALY prevented) are fully appreciated by deci-
sion-makers. Outcomes in clinical units such as morbidity
and mortality averted may be most appreciated by clini-
cians, whereas financial planners may want intervention
costs, amounts of averted spending, and the effects on tax
receipts and public sector budgets. However, for many
such metrics, there is no standard way of comparing
between different types of interventions (such as vaccina-
tion and spending on acute care). Hence, the opportunity
cost of an investment should be made clear; for example,
the value of other investments that may be displaced as a
result of vaccine introduction.
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municating model assumptions and results, so that they
can provide technical peer review in assessing its validity.
Sufficient detail should be provided to allow full reprodu-
cibility by capable modelers, and a good understanding of
how the model works without having to reproduce it.
Although this should in principle be more straightforward
for simpler models, a simple model is not necessarily
‘transparent’ if it is ambiguously documented. A recent
discussion paper by the international HPV modeling com-
munity suggested that publications of model results should
show a variety of measures (such as intermediate disease
endpoints, sources of parameters, and methods used to
calibrate them) even if they are not directly relevant to the
policy decision, to facilitate their appraisal by other mode-
lers [35]. In many cases, this will require the use of online
technical appendices due to print journals’ word limits.
Summary
Economic analyses are important tools for facilitating evi-
dence-based decision-making about HPV vaccination.
Selecting the appropriate analysis is essential to ensure
that all the important features of the decision problem
are correctly represented. However, analyses should not
be more complex than necessary, as simpler analyses can
enable model development by local analysts and greater
ownership of the results by local stakeholders. On a
research level, a priority for future work is investigating
the effect that key behavioral determinants, demographic
changes, and disease co-factors important in low-income
settings have on model results, so that insights from
models of HPV vaccination in HICs can be made more
widely applicable.
Appendix: how the guidelines were formulated
Panel selection
The guideline development process was initiated by the
WHO Initiative for Vaccine Research (IVR) of the
Department of Immunization, Vaccines and Biologicals
(IVB). In his capacity as senior lead economist for the
IVR, RH invited MJ, CL, MB, AL, JB and JK to participate
in a technical experts group that convened at the 27th
International Papillomavirus Conference on September
17 to 22, 2011. These individuals have an extensive publi-
cation record, technical expertise and/or work experience
in 1) modeling and economic analysis of HPV vaccina-
tion in low/middle-income countries, and 2) contributing
to methodological advances in HPV modeling. SR was
selected on recommendation of the initial participants,
because of his involvement in the CerviVac initiative, a
large consortium led by the Pan American Health Orga-
nization (PAHO) developing HPV models for LMICs
that was not otherwise represented in the panel.
Reaching recommendations
The WHO initiated discussions during the Interna-
tional Papillomavirus Conference, and asked this group
of experts to discuss and outline the issues to be
addressed with respect to economic evaluations of
HPV vaccination in LMICs, and the key principles to
use in addressing them. These were developed further
during a teleconference and a face-to-face expert meet-
ing hosted by the WHO in December 2011. An outline
of the discussions was drawn up and agreed on by all
participants. Participants were then assigned sections
of the paper to draft. Each section then received com-
ments from all the other participants. The comments
were collated and harmonized by MJ, and sent out for
further comments until complete consensus was
reached. In total, four iterations of this editing cycle
were made.
Incorporating differing views
The two areas in which participants had differing views
were 1) the need for simple versus complex models and
2) the need for a partial analysis (costs or epidemiologi-
cal outcomes only) versus a full economic analysis. To
reconcile these views, a summary of different views was
drawn up by MJ and agreed on by all participants. Two
participants (SR and RH) were asked to write sections
on the complexity and scope of models, respectively. CL
and AL were also asked to expand upon when an incre-
mental analysis would be required versus a full eco-
nomic analysis. These sections then went through the
four editing iterations described above until complete
consensus was reached. Hence, the final versions incor-
porated the views of all participants. At the end of the
process, there were no further unresolved issues.
Strengths and limitations of the process
A key strength of this process is bringing together
analysts with different skills (in epidemiology, costing,
engaging with policy-makers, and methodological devel-
opment) who are not often involved in working
together. By harmonizing different views and opinions,
we have been able to produce more nuanced guidelines.
One limitation of the process was that participant selec-
tion and discussion of topics was not performed using a
systematic framework, because the purpose was to pro-
duce practical guidelines for field use rather than to pro-
pose a comprehensive set of principles to be adopted
universally. The way in which consensus was reached
(via iterative discussions by a nominated panel of
experts) is similar to the methods used by other WHO
technical advisory groups such as its Immunization and
Vaccines related Implementation Research (IVIR) advi-
sory committee.
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